Skip to Content

GOG-0260, A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Objective
This is a clinical trial of elesclomol sodium that will be administered by IV which is investigational and paclitaxel that will be administered by IVand is standard of care.
IRB Protocol Number
11-0051
Principal Investigator(s)
SUSAN DAVIDSON

Cancer Trials

  • Female Reproductive Cancer
Sponsor(s)
GOG
Contact
REBECCA KISSANE at 720-848-7202
or REBECCA.KISSANE@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as there are no bad side effects and the cancer is not getting worse. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with ovarian, fallopian tube, or primary peritoneal cancer that has failed to respond to initial chemotherapies or has re-grown after surgery, radiation therapy, or other forms of therapy.